NCT01696994Active, not recruiting

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Source: ClinicalTrials.gov · Last updated 24 Jul 2026

Brief summary (registry, in English)

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

Status (registry): Active, not recruiting
Study type: Interventional
Enrollment: 78216 (actual)
First submitted: 28 Sept 2012
Start date: 16 Nov 1993
Primary completion date: 21 May 2012
Lead sponsor: National Cancer Institute (NCI)
Diseases: Prostate cancer, Lung cancer, Colorectal cancer, Ovarian cancer
NCT number: NCT01696994

What you commit to

Study type: Interventional
Participants enrolled: 78216
From 16 Nov 1993 to the primary completion date, 21 May 2012
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Individuals with previous surgical removal of the entire colon or one lung
- Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\\Raloxifene are not excluded from participation.

Other illness

Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
Individuals with known prior cancer of the colon, rectum, lung, or ovary
- This includes primary or metastatic PLCO cancers
Individuals who are participating in another cancer screening or cancer primary prevention trial

Age

Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age

Other

Individuals who are unwilling or unable to sign the informed consent form
Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Age in the registry: 55 years to 74 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
National Institutes of Health Clinical Center Coordinator of this site? Confirm its status	Bethesda	United States	Unknown status

Related publications

Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial.BJC Rep · 2025 · PMID 41261199

This page is information, not medical advice. Discuss any trial with your doctor.